Want to see HK:2171 full AI Analyst Report?
2171 Stock Chart & Stats
HK$14.77
-HK$0.60(-4.06%)
At close: 4:00 PM EDT
HK$14.77
-HK$0.60(-4.06%)
Day’s Range― - ―
52-Week RangeHK$10.87 - HK$28.60
Previous CloseN/A
Volume3.37M
Average Volume (3M)2.55M
Market Cap
HK$7.60B
Enterprise ValueHK$6.32K
Total Cash (Recent Filing)HK$1.40B
Total Debt (Recent Filing)HK$71.98M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 23, 2027EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding594,237,550
10 Day Avg. Volume2,459,216
30 Day Avg. Volume2,551,189
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)9.40
Price to Sales (P/S)58.60
P/FCF Ratio-30.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.82Price Target Upside-6.43% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.18
Revenue Forecast (FY)HK$291.95M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Profit GrowthThe sharp 2025 revenue increase and move to positive gross profit indicate improving commercial traction and product economics. If sustained, this progression can provide a stronger base for funding development, scaling operations, and gradually reducing dependence on external capital.
Lower Debt And Substantial AssetsDebt reduction and a substantial asset base provide some financial resilience while the company continues investing in its pipeline. Lower leverage can reduce interest and refinancing pressure, preserving more flexibility for research, clinical development, and commercialization activities.
Broad CAR-T Development PlatformOperating across the CAR-T value chain gives CARsgen multiple avenues to create value, from advancing proprietary candidates to manufacturing and commercial execution. Its pipeline includes therapies for hematologic malignancies and solid tumors, supporting a broad long-term development opportunity.
Bears Say
Persistent Operating LossesDespite stronger revenue and gross profit, the company remains substantially loss-making, showing that current commercial progress does not yet cover research, development, and operating costs. Persistent losses may delay self-funded growth and require continued financing or other capital support.
Negative Operating Cash FlowDeeply negative operating cash flow means the business is not yet funding its activities internally, even after the year-on-year improvement. Continued cash consumption can constrain investment choices and increase reliance on financing while clinical and commercial programs mature.
Material Equity ErosionThe sustained reduction in equity reflects the cumulative effect of losses and cash burn, weakening the company’s financial cushion. If the trend continues, CARsgen may have less flexibility to absorb setbacks, fund its pipeline, or support operations without additional capital.
CARsgen Therapeutics Holdings Ltd. News
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$10.87 and its highest was HK$28.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$7.60B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Mar 23, 2027 which is in 178 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 19, 2026. The company reported -HK$0.152 earnings per share for the quarter, beating the consensus estimate of -HK$0.222 by HK$0.07.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Overvalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.18.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 594,237,550 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.152 in its last earnings report, beating expectations of -HK$0.222. Following the earnings report the stock price went up 1.361%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
2171 Stock 12 Month Forecast
Average Price Target
HK$13.82
▼(-6.43% Downside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
JW (Cayman) Therapeutics Co. Ltd.
―
CStone Pharmaceuticals
―